Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...

Weight-loss medications surged in popularity this year. A survey from Kaiser Family Foundation found one in eight adults have taken drugs like Ozempic, Wegovy and Mounjaro. Demand for the drugs has ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

No one has ever known so much about healthy eating and been less successful at following her own advice.

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

We’re getting close to the end of 2024, which means it’s time to start thinking about any resolutions you want to take into ...